ABIOMED INC (ABMD)
US0036541003 - Common Stock
ABMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 195 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making ABMD a very profitable company, without any liquidiy or solvency issues. ABMD has a correct valuation and a medium growth rate. With these ratings, ABMD could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
ABMD had positive earnings in the past year.
In the past year ABMD had a positive cash flow from operations.
In the past 5 years ABMD has always been profitable.
Each year in the past 5 years ABMD had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 15.72%, ABMD belongs to the best of the industry, outperforming 94.52% of the companies in the same industry.
ABMD's Return On Equity of 17.32% is amongst the best of the industry. ABMD outperforms 93.61% of its industry peers.
The Return On Invested Capital of ABMD (12.19%) is better than 89.95% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABMD is significantly above the industry average of 8.50%.
The last Return On Invested Capital (12.19%) for ABMD is well below the 3 year average (29.16%), which needs to be investigated, but indicates that ABMD had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROIC | 12.19% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
1.3 Margins
ABMD's Profit Margin of 24.84% is amongst the best of the industry. ABMD outperforms 95.43% of its industry peers.
In the last couple of years the Profit Margin of ABMD has grown nicely.
ABMD's Operating Margin of 23.66% is amongst the best of the industry. ABMD outperforms 93.61% of its industry peers.
In the last couple of years the Operating Margin of ABMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A |
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ABMD is creating value.
ABMD has more shares outstanding than it did 1 year ago.
ABMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 68.47 indicates that ABMD is not in any danger for bankruptcy at the moment.
ABMD's Altman-Z score of 68.47 is amongst the best of the industry. ABMD outperforms 99.54% of its industry peers.
ABMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 68.47 |
ROIC/WACC1.34
WACC9.07%
2.3 Liquidity
A Current Ratio of 7.93 indicates that ABMD has no problem at all paying its short term obligations.
ABMD has a Current ratio of 7.93. This is amongst the best in the industry. ABMD outperforms 83.11% of its industry peers.
ABMD has a Quick Ratio of 7.17. This indicates that ABMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.17, ABMD belongs to the top of the industry, outperforming 82.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 |
3. Growth
3.1 Past
ABMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
Measured over the past years, ABMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.92% on average per year.
The Revenue has grown by 10.32% in the past year. This is quite good.
ABMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.30% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS growth Q2Q26.21%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Revenue growth Q2Q7.16%
3.2 Future
Based on estimates for the next years, ABMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.71% on average per year.
ABMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.13% yearly.
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 78.72, which means the current valuation is very expensive for ABMD.
ABMD's Price/Earnings ratio is a bit cheaper when compared to the industry. ABMD is cheaper than 71.69% of the companies in the same industry.
ABMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.25.
The Price/Forward Earnings ratio is 66.96, which means the current valuation is very expensive for ABMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ABMD indicates a somewhat cheap valuation: ABMD is cheaper than 73.06% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.67. ABMD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ABMD is valued a bit cheaper than the industry average as 69.41% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ABMD is valued cheaply inside the industry as 80.82% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 79.09 | ||
| EV/EBITDA | 55.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ABMD does not grow enough to justify the current Price/Earnings ratio.
ABMD has an outstanding profitability rating, which may justify a higher PE ratio.
ABMD's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)20.54
PEG (5Y)2.55
EPS Next 2Y9.68%
EPS Next 3Y14%
5. Dividend
5.1 Amount
No dividends for ABMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ABIOMED INC
NASDAQ:ABMD (12/21/2022, 7:15:55 PM)
After market: 381.3 +0.28 (+0.07%)381.02
+0.23 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.18B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)20.54
PEG (5Y)2.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y
EPS growth Q2Q
EPS Next Y3.83%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y